TY - JOUR
T1 - Disruption of cell cycle kinetics by benzo[a]pyrene
T2 - Inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2
AU - Jeffy, B. D.
AU - Chen, E. J.
AU - Gudas, J. M.
AU - Romagnolo, D. F.
N1 - Funding Information:
The financial support of Arizona Disease Control Research Commission grants 9722 and 10017 (to D.R.) and Pilot Project P30-ES06694 NIEHS, Southwest Environmental Health Sciences Center (to D.R.) is greatly appreciated. Special thanks are due to T. A. Weinert and G. Tim Bowden for suggestions on cell cycle experiments and useful discussions.
PY - 2000
Y1 - 2000
N2 - The effects of a ligand of the aromatic hydrocarbon receptor (AhR), benzo[a]pyrene (B[a]P), and its metabolite, BPDE (7r,8t-dihydroxy-9t,10t-epoxy-7,8,9,10-tetrahydro-benzo[a]pyrene), on BRCA-1 levels and cell cycle kinetics were determined in MCF-7 breast cancer cells. Exposure of asynchronous MCF-7 cells for 72 hours to a non-cytotoxic dose of 0.5 μM B[a]P triggered a three-fold reduction in BRCA-1 protein. In MCF-7 cells resistant (20% to 30%) to genotoxic concentrations of B[a]P (1 to 5 μM), the loss of BRCA-1 protein was coupled with pausing in S-phase and G2/M, and accumulation of p53, mdm2 and p21. Treatment of MCF-7 cells synchronized in S-phase (72%) with B[a]P prolonged the arrest in S-phase, although this checkpoint was transient since cells resumed to G2/M after 12 hours with reduced levels of BRCA-1. In these cells, levels of p53 were increased, whereas the cellular content of p21 remained unaltered. In contrast, the co-treatment with the AhR antagonist, α-naphthoflavone (ANF), abrogated the deleterious effects of B[a]P on BRCA-1 expression, while preventing the accumulation of p53 and disruption of cell cycle profile. These findings suggest that the AhR mediated the inverse expression patterns of BRCA-1 and p53 upon exposure to B[a]P. The treatment with BPDE induced S-phase arrest and reduced BRCA-1 mRNA levels. The negative effects of BPDE on BRCA-1 expression were not transient since removal of BPDE did not allow complete reversal of the repression. These cumulative data suggest that the B[a]P metabolite, BPDF, may play a key role in disruption of BRCA-1 expression and cell cycle kinetics in breast epithelial cells. Neoplasia (2000) 2, 460-470.
AB - The effects of a ligand of the aromatic hydrocarbon receptor (AhR), benzo[a]pyrene (B[a]P), and its metabolite, BPDE (7r,8t-dihydroxy-9t,10t-epoxy-7,8,9,10-tetrahydro-benzo[a]pyrene), on BRCA-1 levels and cell cycle kinetics were determined in MCF-7 breast cancer cells. Exposure of asynchronous MCF-7 cells for 72 hours to a non-cytotoxic dose of 0.5 μM B[a]P triggered a three-fold reduction in BRCA-1 protein. In MCF-7 cells resistant (20% to 30%) to genotoxic concentrations of B[a]P (1 to 5 μM), the loss of BRCA-1 protein was coupled with pausing in S-phase and G2/M, and accumulation of p53, mdm2 and p21. Treatment of MCF-7 cells synchronized in S-phase (72%) with B[a]P prolonged the arrest in S-phase, although this checkpoint was transient since cells resumed to G2/M after 12 hours with reduced levels of BRCA-1. In these cells, levels of p53 were increased, whereas the cellular content of p21 remained unaltered. In contrast, the co-treatment with the AhR antagonist, α-naphthoflavone (ANF), abrogated the deleterious effects of B[a]P on BRCA-1 expression, while preventing the accumulation of p53 and disruption of cell cycle profile. These findings suggest that the AhR mediated the inverse expression patterns of BRCA-1 and p53 upon exposure to B[a]P. The treatment with BPDE induced S-phase arrest and reduced BRCA-1 mRNA levels. The negative effects of BPDE on BRCA-1 expression were not transient since removal of BPDE did not allow complete reversal of the repression. These cumulative data suggest that the B[a]P metabolite, BPDF, may play a key role in disruption of BRCA-1 expression and cell cycle kinetics in breast epithelial cells. Neoplasia (2000) 2, 460-470.
KW - BPDE
KW - BRCA-1
KW - Benzo[a]pyrene
KW - Cell cycle kinetics
KW - P53
KW - Sporadic breast cancer
UR - http://www.scopus.com/inward/record.url?scp=0034518955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034518955&partnerID=8YFLogxK
U2 - 10.1038/sj.neo.7900104
DO - 10.1038/sj.neo.7900104
M3 - Article
C2 - 11191113
AN - SCOPUS:0034518955
SN - 1522-8002
VL - 2
SP - 460
EP - 470
JO - Neoplasia
JF - Neoplasia
IS - 5
ER -